Top In Vivo Gene Therapy Companies in Poland

The BioVentures Institute Ltd. specializes in advanced genetic engineering and molecular biotechnology, with a focus on developing innovative products, including next-generation vaccines and therapeutics. Their expertise in DNA recombination and extensive industrial experience positions them as key players in the field of biotechnology and gene therapy.

Libera Bio is a biopharmaceutical company focused on developing innovative therapeutics for cancer, particularly targeting intracellular disease mechanisms. Their advanced MPN Technology® allows for the delivery of large molecules, such as antibodies, which may be relevant in the context of in vivo gene therapy approaches for cancer treatment.

Zettagene is focused on accelerating research through advanced genomics and bioinformatics solutions, which are essential for the development of innovative therapies, including in vivo gene therapy. Their collaboration with major sequencing centers and expertise in data science positions them as a key player in the genomics landscape.

Genegoggle is a precision medicine biotech company focused on enhancing human health through innovative therapeutics and advanced genomic understanding. Their work emphasizes the importance of regulatory elements in the genome and includes the development of tools like the Genegoggle Epigenetic Viewer, which supports applications such as gene editing target identification.

The NaNoEXPO system from the biotech start-up NaNoExpo offers innovative solutions for in vivo gene therapy by providing biological nanostructures capable of carrying genetic material, including therapeutic mRNA. Their expertise in designing virus-like particles (VLPs) enhances the development of diagnostic and therapeutic tools, such as vaccines.

SyVento BioTech is a biotechnology company specializing in the development of lipid-based nanocarriers and LNP technology, which are crucial for in vivo gene therapy applications. Their R&D team provides comprehensive support, including optimization of RNA synthesis conditions, highlighting their focus on advancing RNA therapeutics.

OncoTherics Limited focuses on developing therapies that target hypoxic micro-environments in tumors, which are often resistant to conventional treatments like chemotherapy and radiotherapy. Their research could be particularly relevant to advancements in in vivo gene therapy for cancer.

The company has over 18 years of experience in the genetics market, providing commercial solutions and supporting Polish scientists, which highlights their commitment to advancing genetic testing and therapies. Their collaboration with clinics and laboratories underscores their role in the development of innovative genetic solutions that can improve quality of life and potentially save lives.

The company highlights its expertise in addressing client needs and overcoming challenges in the biomedical field. They are involved in the investigation of CAR-T products for treating hematologic malignancies, which is relevant to advancements in gene therapy.

NanoVelos has developed a novel dextran drug delivery system utilizing polysaccharide nanoparticles, which has shown promise in in vitro studies for controlled drug release and targeted therapy. The company's focus on gathering data for FDA and EMA submissions highlights its commitment to advancing innovative medical products and approaches.